Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection

(2010) Patricia M. Day et al.   Cell Host & Microbe

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

(2010) Dominique Descamps et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection

(2010) A. C. Rodriguez et al.   JNCI-Journal of the National Cancer Institute

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®

(2009) Tino F. Schwarz   ADVANCES IN THERAPY

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

(2009) Xavier Castellsagué et al.   GYNECOLOGIC ONCOLOGY

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

(2009) Marie-Pierre David et al.   GYNECOLOGIC ONCOLOGY

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Vaccination in the elderly: an immunological perspective

(2009) Wilbur H. Chen et al.   TRENDS IN IMMUNOLOGY

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

(2008) V M H Coupé et al.   BRITISH JOURNAL OF CANCER

Age-related decline in immunity: implications for vaccine responsiveness

(2008) Rajesh Kumar et al.   Expert Review of Vaccines

Immunobiology of HPV and HPV vaccines

(2008) Margaret Stanley   GYNECOLOGIC ONCOLOGY

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

(2008) Tino F. Schwarz et al.   GYNECOLOGIC ONCOLOGY

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

(2008) F. Xavier Bosch et al.   VACCINE

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

(2008) Tino F. Schwarz et al.   VACCINE